德谷胰岛素：一种新型基础胰岛素。
Degludec insulin: A novel basal insulin.
作者信息
Kalra Sanjay, Unnikrishnan Ambika Gopalakrishnan, Baruah Manash, Kalra Bharti
机构信息
Department of Endocrinology, Bharti Hospital and BRIDE, Karnal, India.
出版信息
Indian J Endocrinol Metab. 2011 Jul;15(Suppl 1):S12-6. doi: 10.4103/2230-8210.83056.
Abstract
This paper reviews a novel insulin analogue, degludec, which has the potential to emerge as an ideal basal insulin. It reviews the limitations of existing basal insulin and analogues, and highlights the need for a newer molecule. The paper discusses the potential advantages of degludec, while reviewing its pharmacologic and clinical studies done so far. The paper assesses the potential role of insulin degludec and degludec plus in clinical diabetes practice.
摘要
本文综述了一种新型胰岛素类似物德谷胰岛素，它有可能成为一种理想的基础胰岛素。文中回顾了现有基础胰岛素及类似物的局限性，并强调了对更新型分子的需求。本文在回顾德谷胰岛素迄今为止的药理和临床研究时，讨论了其潜在优势。本文评估了德谷胰岛素及德谷胰岛素利拉鲁肽在临床糖尿病治疗中的潜在作用。
相似文献
1
Degludec insulin: A novel basal insulin.德谷胰岛素：一种新型基础胰岛素。
Indian J Endocrinol Metab. 2011 Jul;15(Suppl 1):S12-6. doi: 10.4103/2230-8210.83056.
2
Degludec: A Novel Basal Insulin.德谷胰岛素：一种新型基础胰岛素。
Recent Pat Endocr Metab Immune Drug Discov. 2012 Jan 25.
3
Degludec: a novel basal insulin.德谷胰岛素：一种新型基础胰岛素。
Recent Pat Endocr Metab Immune Drug Discov. 2012 Jan;6(1):18-23. doi: 10.2174/187221412799015326.
4
Insulin degludec, a long-acting once-daily basal analogue for type 1 and type 2 diabetes mellitus.德谷胰岛素，一种用于 1 型和 2 型糖尿病的长效每日一次基础胰岛素类似物。
Can J Diabetes. 2015 Feb;39(1):4-9. doi: 10.1016/j.jcjd.2014.02.019. Epub 2014 Jul 22.
5
Can a new ultra-long-acting insulin analogue improve patient care? Investigating the potential role of insulin degludec.新型超长效胰岛素类似物能否改善患者治疗效果？探索德谷胰岛素的潜在作用。
Drugs. 2012 Dec 24;72(18):2319-25. doi: 10.2165/11642240-000000000-00000.
6
Degludec, a new ultra-long-acting basal insulin for the treatment of diabetes mellitus type 1 and 2: advances in clinical research.德谷胰岛素，一种用于治疗1型和2型糖尿病的新型超长效基础胰岛素：临床研究进展
Endocrinol Nutr. 2014 Mar;61(3):153-9. doi: 10.1016/j.endonu.2013.03.012. Epub 2013 Jul 25.
7
Clinical relevance of pharmacokinetic and pharmacodynamic profiles of insulin degludec (100, 200 U/mL) and insulin glargine (100, 300 U/mL) - a review of evidence and clinical interpretation.胰岛素地特胰岛素（100、200 U/mL）和甘精胰岛素（100、300 U/mL）的药代动力学和药效学特征的临床相关性-证据回顾与临床解读。
Diabetes Metab. 2019 Sep;45(4):330-340. doi: 10.1016/j.diabet.2018.11.004. Epub 2018 Nov 26.
8
Understanding the Clinical Profile of Insulin Degludec, the Latest Basal Insulin Approved for Use in Canada: a Narrative Review.了解德谷胰岛素的临床概况，这是加拿大最新批准使用的基础胰岛素：一项叙述性综述。
Diabetes Ther. 2020 Nov;11(11):2539-2553. doi: 10.1007/s13300-020-00915-w. Epub 2020 Sep 17.
9
Successful Outcomes with Insulin Degludec in Pregnancy: A Case Series.德谷胰岛素在孕期的成功治疗结果：病例系列
Diabetes Ther. 2019 Feb;10(1):283-289. doi: 10.1007/s13300-018-0532-z. Epub 2018 Nov 15.
10
Real-life experience of patients starting insulin degludec. A multicenter analysis of 1064 subjects from the German/Austrian DPV registry.起始使用德谷胰岛素患者的真实生活经历。对来自德国/奥地利糖尿病患者数据注册库的1064名受试者进行的多中心分析。
Diabetes Res Clin Pract. 2017 Jul;129:52-58. doi: 10.1016/j.diabres.2017.03.031. Epub 2017 May 4.
引用本文的文献
1
Differential Effect of Hypoalbuminemia on Hypoglycemia on Type 2 Diabetes Patients Treated with Insulin Glargine 300 U/ml and Insulin Degludec.低白蛋白血症对接受300 U/ml甘精胰岛素和德谷胰岛素治疗的2型糖尿病患者低血糖的不同影响。
Diabetes Ther. 2019 Aug;10(4):1535-1541. doi: 10.1007/s13300-019-0654-y. Epub 2019 Jun 21.
2
Comparison of the efficacy and safety of insulin degludec/aspart (twice-daily injections), insulin glargine 300 U/mL, and insulin glulisine (basal-bolus therapy).比较德谷胰岛素门冬胰岛素（每日两次注射）、甘精胰岛素 300U/mL 和赖脯胰岛素（基础-餐时胰岛素方案）的疗效和安全性。
J Diabetes Investig. 2019 Nov;10(6):1527-1536. doi: 10.1111/jdi.13038. Epub 2019 Apr 2.
3
Efficacy and safety of insulin glargine 300 U/mL vs insulin degludec in patients with type 2 diabetes: A randomized, open-label, cross-over study using continuous glucose monitoring profiles.胰岛素甘精 300U/mL 与德谷胰岛素治疗 2 型糖尿病患者的疗效和安全性：使用连续血糖监测谱的随机、开放标签、交叉研究。
J Diabetes Investig. 2019 Mar;10(2):343-351. doi: 10.1111/jdi.12884. Epub 2018 Jul 28.
4
Basal Insulin Inadequacy versus Failure - Using Appropriate Terminology.基础胰岛素不足与失败——使用恰当的术语
Eur Endocrinol. 2015 Aug;11(2):79-80. doi: 10.17925/EE.2015.11.02.79. Epub 2015 Aug 19.
5
Pragmatic use of insulin degludec/insulin aspart co-formulation: A multinational consensus statement.德谷胰岛素/门冬胰岛素共混制剂的实用应用：一项跨国共识声明。
Indian J Endocrinol Metab. 2016 Jul-Aug;20(4):542-5. doi: 10.4103/2230-8210.182980.
6
Injectable Coformulations in Diabetology.糖尿病学中的注射用复方制剂
Diabetes Ther. 2015 Jun;6(2):101-11. doi: 10.1007/s13300-015-0106-2. Epub 2015 Mar 24.
7
Structural and functional study of the GlnB22-insulin mutant responsible for maturity-onset diabetes of the young.导致青年发病型成年糖尿病的GlnB22-胰岛素突变体的结构与功能研究
PLoS One. 2014 Nov 25;9(11):e112883. doi: 10.1371/journal.pone.0112883. eCollection 2014.
8
Modern basal insulin analogs: An incomplete story.现代基础胰岛素类似物：一个不完整的故事。
Indian J Endocrinol Metab. 2014 Nov;18(6):784-93. doi: 10.4103/2230-8210.140239.
9
Insulin degludec: a significant advancement in ultralong-acting Basal insulin.德谷胰岛素：超长效基础胰岛素的重大进展。
Diabetes Ther. 2013 Dec;4(2):167-73. doi: 10.1007/s13300-013-0047-6. Epub 2013 Nov 20.
本文引用的文献
1
Insulin degludec: four times lower pharmacodynamic variability than insulin glargine under steady-state conditions in type 1 diabetes.在 1 型糖尿病患者中，稳态条件下德谷胰岛素的药效变异性比甘精胰岛素低四倍。
Diabetes Obes Metab. 2012 Sep;14(9):859-64. doi: 10.1111/j.1463-1326.2012.01627.x. Epub 2012 Jun 7.
2
The future of basal insulin supplementation.基础胰岛素补充的未来。
Diabetes Technol Ther. 2011 Jun;13 Suppl 1:S103-8. doi: 10.1089/dia.2010.0251. Epub 2011 May 13.
3
Insulin degludec, an ultra-long-acting basal insulin, once a day or three times a week versus insulin glargine once a day in patients with type 2 diabetes: a 16-week, randomised, open-label, phase 2 trial.德谷胰岛素，一种超长效基础胰岛素，每日一次或每周三次，对比甘精胰岛素每日一次，用于 2 型糖尿病患者：一项 16 周、随机、开放标签、2 期临床试验。
Lancet. 2011 Mar 12;377(9769):924-31. doi: 10.1016/S0140-6736(10)62305-7.
4
A new-generation ultra-long-acting basal insulin with a bolus boost compared with insulin glargine in insulin-naive people with type 2 diabetes: a randomized, controlled trial.与甘精胰岛素相比，新代超长效基础胰岛素联合餐时胰岛素注射治疗初诊 2 型糖尿病患者的随机对照研究。
Diabetes Care. 2011 Mar;34(3):669-74. doi: 10.2337/dc10-1905. Epub 2011 Feb 1.
5
Insulin degludec in type 1 diabetes: a randomized controlled trial of a new-generation ultra-long-acting insulin compared with insulin glargine.德谷胰岛素治疗 1 型糖尿病：新一代超长效胰岛素与甘精胰岛素的随机对照试验。
Diabetes Care. 2011 Mar;34(3):661-5. doi: 10.2337/dc10-1925. Epub 2011 Jan 26.
6
Insulin detemir: A historical perspective on a modern basal insulin analogue.胰岛素地特胰岛素：一种现代基础胰岛素类似物的历史视角。
Prim Care Diabetes. 2010 Apr;4 Suppl 1:S31-42. doi: 10.1016/S1751-9918(10)60007-1.
7
Resurrections in Toronto: the emergence of insulin.多伦多的复苏：胰岛素的出现
Horm Res. 2005;64 Suppl 2:98-102. doi: 10.1159/000087765.
8
The mechanism of protraction of insulin detemir, a long-acting, acylated analog of human insulin.德谷胰岛素（一种长效的、酰化的人胰岛素类似物）的延长作用机制。
Pharm Res. 2004 Aug;21(8):1498-504. doi: 10.1023/b:pham.0000036926.54824.37.
9
Lower within-subject variability of insulin detemir in comparison to NPH insulin and insulin glargine in people with type 1 diabetes.与NPH胰岛素和甘精胰岛素相比，地特胰岛素在1型糖尿病患者中的个体内变异性更低。
Diabetes. 2004 Jun;53(6):1614-20. doi: 10.2337/diabetes.53.6.1614.
10
Insulin glargine.甘精胰岛素
Lancet. 2000 Aug 5;356(9228):443-5. doi: 10.1016/S0140-6736(00)02546-0.
Zotero 插件